To ask His Majesty's Government, further to the report RAPID C-19 Oversight Group report: review of Evusheld by the RAPID C-19 Oversight Group, published on 6 October, how many members of the RAPID C-19 Oversight Group were (1) full time clinicians or doctors, and (2) clinicians who treat immunocompromised patients.

To ask His Majesty's Government, further to the report RAPID C-19 Oversight Group report: review of Evusheld by the RAPID C-19 Oversight Group, published on 6 October, how many members of the RAPID C-19 Oversight Group (1) have published research in the field of COVID-19, and (2) were members of SAGE and the JCVI.

To ask His Majesty's Government, further to the report RAPID C-19 Oversight Group report: review of Evusheld by the RAPID C-19 Oversight Group, published on 6 October, how many members of RAPID C-19 Oversight Group were (1) patient charity representatives, and (2) patient representatives.

RAPID C-19 is a multi-agency initiative which includes representatives from the National Institute for Health and Care Research, the National Institute for Health and Care Excellence, the Medicines and Healthcare products Regulatory Agency, NHS England and the devolved administrations. Its review of Evusheld sought advice from a National Health Service expert working group and the Prophylaxis Oversight Group. RAPID C-19 contains nine clinicians with a range of expertise. While no members of RAPID C-19 or the Prophylaxis Oversight Group are immunologists, NHS expert working group has three immunology specialists.

There is one member of the Scientific Advisory Group on Emergencies in RAPID C-19 and three in the NHS expert working group and three in the Prophylaxis Oversight Group. While there are no members of the Joint Committee on Vaccination and Immunisation in RAPID C-19, it includes two scientific experts with published peer reviewed literature on COVID-19. There are no patient charity or patient representatives in RAPID C-19’s membership.